News

Filter

Current filters:

Cinryze

1 to 9 of 16 results

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Stagnant treatment future seen for inherited orphan blood diseases

23-01-2013

Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth…

CinryzeMarkets & MarketingPharmaceuticalRare diseasesViroPharma

ViroPharma gets FDA backing for industrial scale Cinryze manufacturing

07-08-2012

US biotech firm ViroPharma (Nasdaq: VPHM) says that the US Food and Drug Administration has approved…

BiotechnologyCinryzeNorth AmericaProductionRegulationReproductiveViroPharma

ViroPharma's Cinryze cleared for hereditary angioedema in Europe

17-06-2011

The European Commission has granted US biotech firm ViroPharma (Nasdaq: VPHM) Centralized Marketing Authorization…

BiotechnologyCinryzeEuropePharmaceuticalRare diseasesRegulationViroPharma

ViroPharma in up to $83 million deal with Halozyme for rHuPH 20 with Cinryze

12-05-2011

US companies Halozyme Therapeutics (Nasdaq: HALO) and ViroPharma (Nasdaq: VPHM) have signed a worldwide…

CinryzeHalozyme TherapeuticsLicensingPharmaceuticalRare diseasesResearchViroPharma

Batch of positive and negative drug opinions from Europe’s CHMP

21-03-2011

The European Medicines Agency’s advisory panel, the Committee for Medicinal Products for Human Use…

CinryzeEliquisEuropePharmaceuticalRegulationVectibix

FDA priority review for ViroPharma's Cinryze

09-02-2009

The US Food and Drug Administration has granted priority review for ViroPharma's Cinryze C1 inhibitor…

C1Esterase Inhibitor [Human] Freeze Dried PowCinryze

1 to 9 of 16 results

Back to top